Evidence map›Paper›PMID 17400267›Full record

ArticleToxicology and applied pharmacology2007

Arsenite and insulin exhibit opposing effects on epidermal growth factor receptor and keratinocyte proliferative potential.

Timothy J Patterson, Robert H Rice

Open access · greenAbstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. Article
  3. Chronic and acute arsenic exposure enhance EGFR expression via distinct molecular mechanisms.Toxicology in vitro : an international journal published in association with BIBRA · 2020
    Article
  4. Arsenic Stimulates Myoblast Mitochondrial Epidermal Growth Factor Receptor to Impair Myogenesis.Toxicological sciences : an official journal of the Society of Toxicology · 2020
    Article
  5. Article
  6. Article
  7. Review
  8. Cancer Stem-Like Cells Accumulated in Nickel-Induced Malignant Transformation.Toxicological sciences : an official journal of the Society of Toxicology · 2016
    Article
  9. Article
  10. Review
  11. Arsenite suppression of BMP signaling in human keratinocytes.Toxicology and applied pharmacology · 2013
    Article
  12. Article
  13. Article
  14. Overabundance of putative cancer stem cells in human skin keratinocyte cells malignantly transformed by arsenic.Toxicological sciences : an official journal of the Society of Toxicology · 2012
    Article
  15. Arsenic, stem cells, and the developmental basis of adult cancer.Toxicological sciences : an official journal of the Society of Toxicology · 2011
    Article
  16. Article
  17. Carcinogenic effects of "whole-life" exposure to inorganic arsenic in CD1 mice.Toxicological sciences : an official journal of the Society of Toxicology · 2011
    Article
  18. Review
  19. Arsenic-specific stem cell selection during malignant transformation.Journal of the National Cancer Institute · 2010
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Timothy J PattersonDepartment of Environmental Toxicology, University of California, One Shields Avenue, Davis, CA 95616-8588, USA.
Robert H Rice
University of California, Davis · US

Funding

Workshop on Environmental Technology Transfer and EntrepreneurshipP42ES004699 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1987 to 2021
$50.1M
NIEHS Center for Health Effects of AgrochemicalsP30ES005707 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI MATSUMURA, FUMIO NONE · 1992 to 2006
$9.9M
ENVIRONMENTAL TOXICOLOGYT32ES007059 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura S Van Winkle · 1985 to 2026
$7.9M
KERATINOCYTE TRANSGLUTAMINASE--STRUCTURE AND REGULATIONR01AR027130 · NIAMS · UNIVERSITY OF CALIFORNIA DAVIS · PI RICE, ROBERT H · 1986 to 2004
$1.0M
MECHANISMS OF OXIDANT INDUCED LYMPHOCYTE REGULATIONF32ES005707 · NIEHS · WADSWORTH CENTER · PI KRIEGER, JIM A · 1995 to 1996
–
NIAMS NIH HHS AR27130NIAMS NIH HHS R01 AR027130NIEHS NIH HHS ES04699NIEHS NIH HHS ES05707NIEHS NIH HHS ES07059NIEHS NIH HHS F32 ES005707NIEHS NIH HHS P30 ES005707NIEHS NIH HHS P42 ES004699NIEHS NIH HHS T32 ES007059
6 · The paper itself

Abstract

Previous work has suggested that arsenic exposure contributes to skin carcinogenesis by preserving the proliferative potential of human epidermal keratinocytes, thereby slowing the exit of putative target stem cells into the differentiation pathway. To find a molecular basis for this action, present work has explored the influence of arsenite on keratinocyte responses to epidermal growth factor (EGF). The ability of cultured keratinocytes to found colonies upon passaging several days after confluence was preserved by arsenite and EGF in an additive fashion, but neither was effective when the receptor tyrosine kinase activity was inhibited. Arsenite prevented the loss of EGF receptor protein and phosphorylation of tyrosine 1173, preserving its capability to signal. The level of nuclear beta-catenin was higher in cells treated with arsenite and EGF in parallel to elevated colony forming ability, and expression of a dominant negative beta-catenin suppressed the increase in both colony forming ability and yield of putative stem cells induced by arsenite and EGF. As judged by expression of three genes regulated by beta-catenin, this transcription factor had substantially higher activity in the arsenite/EGF-treated cells. Trivalent antimony exhibited the same effects as arsenite. A novel finding is that insulin in the medium induced the loss of EGF receptor protein, which was largely prevented by arsenite exposure.

Indexed as

AntimonyArsenitesbeta CateninBone Morphogenetic Protein 4Bone Morphogenetic ProteinsCell Line, TransformedCell ProliferationCells, CulturedCycloheximideDose-Response Relationship, DrugEnzyme InhibitorsEpidermal Growth FactorErbB ReceptorsGene ExpressionHumansInsulin6-(methylamino)pyrido(3,4-d)pyrimidineantimoniteAntimonyArsenitesbeta CateninBMP4 protein, humanBone Morphogenetic Protein 4Bone Morphogenetic ProteinsCycloheximideEnzyme InhibitorsEpidermal Growth FactorErbB ReceptorsInsulinMatrix Metalloproteinase 7PPAR deltaPyrimidinesQuinazolinesras ProteinsRNA, MessengerRTKI cpdTyrphostins

Identifiers

PMID17400267
PMCPMC1950287
OpenAlexW1981657350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.